Catalyst Pharmaceuticals to Participate in Jefferies Global Healthcare Conference
Rhea-AI Summary
Catalyst Pharmaceuticals (Nasdaq: CPRX) will participate in the Jefferies Global Healthcare Conference in London on Monday, November 17, 2025. Rich Daly, President and CEO, and other members of management will present.
Presentation time: 2:00 pm GMT. A live webcast will be available in the Investors section at www.catalystpharma.com, and a replay will be available for at least 30 days.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CPRX gained 0.80%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
CORAL GABLES, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO, along with other members of Catalyst's management team, will participate in the Jefferies Global Healthcare Conference in London on Monday, November 17, 2025.
Presentation Day: Monday, November 17, 2025
Time: 2:00 pm (GMT)
Webcast Link
The webcast will be available under the Investors section on the Company's website, www.catalystpharma.com, and a replay will be available for at least 30 days.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., was recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America's Fastest-Growing Companies.
For more information, please visit Catalyst's website at www.catalystpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2024 and its subsequent filings with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
Investor Contact Melissa Kendis, Catalyst Pharmaceuticals, Inc. (305) 420-3200 IR@catalystpharma.com Media Contact David Schull, Russo Partners (858) 717-2310 david.schull@russopartnersllc.com
FAQ
When will Catalyst Pharmaceuticals (CPRX) present at the Jefferies Global Healthcare Conference?
Who from Catalyst (CPRX) will speak at the November 17, 2025 presentation?
Where can investors watch the Catalyst (CPRX) Jefferies conference presentation webcast?
Will there be a replay of Catalyst's (CPRX) Jefferies presentation and for how long?
What time zone is used for Catalyst's (CPRX) Jefferies presentation on November 17, 2025?
How can shareholders access materials or the webcast for Catalyst's (CPRX) Jefferies presentation?
